ARGENX SE
Business
ARGENX SE is a commercial-stage, fully integrated biopharmaceutical company developing and commercializing differentiated antibody-based therapies for severe autoimmune and neuromuscular diseases. Its main products and product candidates include efgartigimod (VYVGART and VYVGART SC), a first‑in‑class FcRn blocker, empasiprubart, a C2 complement inhibitor, ARGX‑119, a MuSK agonist, and multiple earlier‑stage candidates from its Immunology Innovation Program (IIP). The company operates discovery, antibody‑engineering and clinical development functions alongside commercial activities and partnership/licensing arrangements. It distributes products globally via its own sales forces in key markets and through regional partners and distributors.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $1.29B |
| Total assets | $8.68B |
| Total liabilities | $1.36B |
| Stockholders' equity | — |
| Operating cash flow | — |